On the Frontlines of Psoriasis
Guest: Christopher Bunick, MD, PhD, FAAD Host: Ryan Quigley With high selectivity, durable response, and once-daily dosing, next-generation TYK2 inhibitors offer a promising oral option for patients with moderate-to-severe plaque psoriasis. Ryan Quigley sits down with Dr. Christopher Bunick, Associate Professor of Dermatology and Translational Biomedicine at Yale University School of Medicine, to learn more about how these agents may align with evolving patient preferences and expand options beyond injectables.
28 Folgen
Kommentare
0Sei die erste Person, die kommentiert
Melde dich jetzt an und werde Teil der On the Frontlines of Psoriasis-Community!